Boulding Mark Elliott, executive vice president and chief legal officer at PTC Therapeutics (PTCT), has filed 100 Form 4 transactions, all in that single company. The pattern is one-sided. His total sell value is $8,982,791.87, and his total buy value is zero. He has not made an open-market purchase in the recent period, and his recent activity shows 18 sales against zero buys.
The recent trades cluster around option exercises and same-day sales. On August 17, 2026, Elliott exercised options worth $72,265.97 and sold shares in two transactions totaling $204,127.26. On July 6, 2026, he exercised options valued at $130,917.02 and $89,325.72, then sold shares in seven transactions ranging from $26,010.30 to $87,448.76, for a combined $406,063.53. On June 17, 2026, he exercised options worth $396,055.40 and $93,638.48, and sold shares in four transactions, including a single sale of $518,100, for a total of $814,379.50. On May 15, 2026, he exercised options worth $72,240.28 and sold shares for $169,820.48 and $33,137.52. On May 8, 2026, he sold shares for $47,568 and $15,600.
The M codes are option exercises, which are mechanical and not discretionary purchases. The S codes are open-market sales. The consistent pairing of M and S on the same date indicates shares were acquired through exercise and then sold, a common pattern for executives converting options into cash. The dollar values are modest relative to the company's market cap, and the absence of any P codes means Elliott has not put new cash into PTCT stock during this window. The direction is uniformly toward liquidation of holdings, with no accumulation.
AI-assisted summary